Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
Holger Rosenbrock, Michael Desch, Glen Wunderlich
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1557-1566
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

New directions in psychiatric drug development: promising therapeutics in the pipeline
Linda S. Brady, Sarah H. Lisanby, Joshua A. Gordon
Expert Opinion on Drug Discovery (2023) Vol. 18, Iss. 8, pp. 835-850
Closed Access | Times Cited: 6
Kognitive Beeinträchtigung in Zusammenhang mit Schizophrenie (CIAS): Diagnostik und Therapie
Gabriele Sachs, Andreas Erfurth
psychopraxis neuropraxis (2024) Vol. 27, Iss. 2, pp. 74-80
Open Access | Times Cited: 1
Dynamic role of GlyT1 as glycine sink or source: pharmacological implications for the gain control of NMDA receptors
Stéphane Supplisson
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Closed Access | Times Cited: 1
In silico evidence of bitopertin’s broad interactions within the SLC6 transporter family
Gustavo Almeida Carvalho, Paul Magogo Tambwe, Lucas Rodrigues Couto Nascimento, et al.
Journal of Pharmacy and Pharmacology (2024) Vol. 76, Iss. 9, pp. 1199-1211
Closed Access | Times Cited: 1
Overview of Psychiatric Medications in the Pipeline in Phase III Trials as of June 1, 2024: A Systematic Review.
Waguih William IsHak, Ashley N. D. Meyer, Luiza Freire, et al.
PubMed (2024) Vol. 21, Iss. 7-9, pp. 27-47
Closed Access | Times Cited: 1
Editorial: Glutamatergic system in affective and psychotic disorders: pre-clinical and clinical advances
Dominik Strzelecki, Monika Talarowska, Jakub Kaźmierski, et al.
Frontiers in Neuroscience (2024) Vol. 17
Open Access
Motivation levels and white matter microstructure in children living with HIV
Catherine J. Wedderburn, Tatum Sevenoaks, Jean‐Paul Fouché, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
A lifetime of mental health treatments for people with schizophrenia: update and narrative review
Lynn E. DeLisi
Current Opinion in Psychiatry (2024) Vol. 37, Iss. 3, pp. 140-146
Closed Access
Identifying drug targets for schizophrenia through gene prioritization
Julia Kraft, Alice Braun, Swapnil Awasthi, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Inhibition of astrocytic glycine transporter-1: friend or foe for ameliorating NMDA receptor hypofunction?
Philipp Singer, Benjamin K. Yee
Frontiers in Cellular Neuroscience (2024) Vol. 18
Open Access
Strategies for Achieving Better Cognitive Health in Individuals with Schizophrenia Spectrum: A Focus on the Canadian Landscape: Stratégies pour atteindre une meilleure santé cognitive chez les personnes souffrant du spectre de la schizophrénie : un regard sur le paysage canadien
Martín Lepage, Synthia Guimond, Thomas J. Raedler, et al.
The Canadian Journal of Psychiatry (2024)
Closed Access
Dynamic role of GlyT1 as glycine sink or source: Pharmacological implications for the gain control of NMDA receptors
Stéphane Supplisson
Neuroscience (2024)
Open Access
Associations between neurolinguistic deficits and personality traits in people with epilepsy
Nikitas Floros, Nikolaos Papagiannakis, Andreas Kyrozis, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access
Clinical significance and expression of SLC35F6 in bladder urothelial carcinoma
Jinling Zhang, Siqi Liu, Meng Wu, et al.
Diagnostic Pathology (2024) Vol. 19, Iss. 1
Open Access
Kognitive Beeinträchtigungen bei schizophrenen Psychosen
Lana Kambeitz‐Ilankovic, Wolfgang Strube, Bernhard T. Baune, et al.
Der Nervenarzt (2024)
Open Access
How antipsychotics work in schizophrenia: a primer on mechanisms
Jonathan M. Meyer
CNS Spectrums (2024) Vol. 30, Iss. 1
Open Access
A Clinically Oriented Review of New Antipsychotics for Schizophrenia
Maria Luca, Antonina Luca, Alessandro Serretti
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 2637-2649
Open Access
NMDA Receptors in Neurodevelopmental Disorders: Pathophysiology and Disease Models
Roshan Tumdam, Yara Hussein, Tali Garin-Shkolnik, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 22, pp. 12366-12366
Open Access
Efficacy and safety of iclepertin (BI 425809) with adjunctive computerized cognitive training in patients with schizophrenia
Philip D. Harvey, Sean McDonald, Eric Fu, et al.
Schizophrenia Research Cognition (2024) Vol. 40, pp. 100340-100340
Closed Access
New treatment strategies for mental health
Kenji Hashimoto, Andrea Schmitt
European Archives of Psychiatry and Clinical Neuroscience (2023) Vol. 273, Iss. 7, pp. 1399-1401
Open Access | Times Cited: 1
Previous Page - Page 2

Scroll to top